On June 7, 2018 Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), reported a presentation at the 23rd Congress of the European Hematology Association (EHA) (Free EHA Whitepaper) being held June 14-17, 2018 in Stockholm, Sweden (Press release, Onconova, JUN 7, 2018, View Source [SID1234527221]). Dr. Steven Fruchtman, Onconova’s Chief Medical Officer and Senior VP, Research & Development, will be attending the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On June 7, 2018 ArQule, Inc. (Nasdaq: ARQL) reported clinical data from the company-sponsored ARQ 531-101 Phase 1 dose escalation study in subjects with relapsed or refractory hematologic malignancies will be presented on June 15, 2018 at the EHA (Free EHA Whitepaper) Congress in Stockholm, Sweden (Press release, ArQule, JUN 7, 2018, View Source [SID1234527220]). ARQ 531 is an orally bioavailable, potent and reversible inhibitor of both wild type and C481S-mutant Bruton’s tyrosine kinase (BTK).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details
Friday, June 15, 2018: Chronic lymphocytic leukemia and related disorders – Clinical
Title: A Phase 1 Dose Escalation Study of ARQ 531 in Selected Patients with Relapsed or Refractory Hematologic Malignancies
Location: Poster area
Time:17:30-19:00 CET
Abstract Code: PF355

About BTK and ARQ 531

Bruton’s tyrosine kinase, BTK, is a therapeutic target that has been clinically proven to inhibit B-cell receptor signaling in blood cancers. ARQ 531 is an orally bioavailable, potent and reversible BTK inhibitor. Biochemical and cellular studies have shown that ARQ 531 inhibits both the wild type and C481S-mutant forms of BTK. The C481S mutation is a known resistance mechanism for first generation irreversible BTK inhibitors. In preclinical studies, ARQ 531 has demonstrated good oral bioavailability as well as favorable pharmacokinetic, pharmacodynamic and metabolic properties.

On June 7, 2018 Radius Health, Inc. (Nasdaq:RDUS) reported that Jesper Høiland, President and Chief Executive Officer and Pepe Carmona, Senior Vice President and Chief Financial Officer of the Company, will present a corporate update at the at the Goldman Sachs 39th Annual Global Healthcare Conference on Tuesday, June 12, 2018 (Press release, Radius, JUN 7, 2018, View Source [SID1234527219]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Information on the presentation is as follows:

Event: Goldman Sachs 39th Annual Global Healthcare Conference
Date: Tuesday, June 12, 2018
Time: 10:40 a.m. PDT
Location: Terranea Resort, Rancho Palos Verdes, CA
A live webcast of the presentation will be available by visiting the Investors section of Radius’ website at View Source A replay of the webcast will be archived on Radius’ website for 30 days following the presentation.

On June 7, 2018 Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor infiltrating lymphocyte (TIL) technology, reported that the first patient was dosed in the ongoing C-144-01 Phase 2 trial of LN-144 (lifileucel) for the treatment of patients with metastatic melanoma at a clinical trial site in the United Kingdom (Press release, Iovance Biotherapeutics, JUN 7, 2018, View Source;p=RssLanding&cat=news&id=2353696 [SID1234527218]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The dosing of the first patient with lifileucel in Europe for the treatment of metastatic melanoma marks an important milestone for Iovance and our global development plans as our European Union (EU) manufacturing is now able to support enrollment in that region," said Dr. Maria Fardis, PhD, MBA, president and chief executive officer of Iovance Biotherapeutics. "This is a major step forward and we are excited by the opportunity to offer more patients TIL therapy around the world."

In December 2017, the company announced that the Generation 2 manufacturing process, with a duration of 22 days, was selected and all studies were shifted to utilize that method of manufacturing. The company has manufacturing capability in both the US and EU. This is the first patient treated with TIL developed in an EU-based manufacturing facility.

C-144-01 is a Phase 2 multicenter study evaluating the safety and efficacy of autologous tumor infiltrating lymphocytes (lifileucel), Iovance’s lead product candidate for treatment of patients with metastatic melanoma. The study is currently enrolling in the United States and Europe. To date, Iovance has over 25 active clinical sites in the United States and Europe. The sample size for enrollment was increased to 85 for this study. Additional information on this study is available at www.clinicaltrials.gov using the identifier number NCT02360579.

On June 7, 2018 Bristol-Myers Squibb Company (NYSE:BMY) reported it will announce results for the second quarter of 2018 on Thursday, July 26, 2018 (Press release, Bristol-Myers Squibb, JUN 7, 2018, View Source [SID1234527217]). During a conference call at 10:30 a.m. EDT on July 26, company executives will review financial information and will address inquiries from investors and analysts.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors and the general public are invited to listen to a live webcast of the call at View Source or by dialing in the U.S. toll free 323-794-2093 or international 866-548-4713, confirmation code: 4235170. Materials related to the call will be available at the same website prior to the conference call. A replay of the call will be available beginning at 1:30 p.m. EDT on July 26 through 1:30 p.m. EDT on, August 9, 2018. The replay will also be available through View Source or by dialing in the U.S. toll free 888-203-1112 or international 719-457-0820, confirmation code: 4235170.